Literature DB >> 18575896

Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease.

Shina Menon1, Rudolph P Valentini, Guillermo Hidalgo, Lena Peschansky, Tej K Mattoo.   

Abstract

Chronic kidney disease (CKD) is associated with altered calcium-phosphate homeostasis and hyperparathyroidism due to decreased activity of 1alpha-hydroxylase and impaired activation of 25-hydroxyvitamin D3 [25(OH)D3]. In some patients these problems start earlier because of vitamin D deficiency. A retrospective review of patients followed in the chronic renal insufficiency clinic at Children's Hospital of Michigan assessed the prevalence of vitamin D deficiency in CKD stages 2-4 and evaluated the effect of treatment with ergocalciferol on serum parathormone (PTH). Blood levels of 1,25 dihydroxyvitamin D3, 25(OH)D3, and parathormone (PTH) were examined in 57 children (40 boys; mean age 10.6 years). Of 57 subjects, 44 (77.2%) had 25(OH)D3 levels < or =30 ng/ml, with overall mean of 26.4 +/- 14.3 ng/ml. PTH for patients with 25(OH)D3 levels >30 ng/ml was 67.84 +/- 29.09 ng/ml and in the remaining patients was elevated, at 120.36 +/- 86.42 ng/ml (p = 0.05). Following ergocalciferol treatment (22), PTH decreased from 122.13 +/- 82.94 ng/ml to 80.14 +/- 59.24 ng/ml (p < 0.001) over a period of 3 months. We conclude that vitamin D deficiency is common in children with CKD stages 2-4 and is associated with hyperparathyroidism in the presence of normal 1,25 dihydroxyvitamin D3. Its occurrence before significant renal impairment is noteworthy. Early diagnosis and appropriate treatment is emphasized.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575896     DOI: 10.1007/s00467-008-0842-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  26 in total

1.  Vitamin D insufficiency among free-living healthy young adults.

Authors:  Vin Tangpricha; Elizabeth N Pearce; Tai C Chen; Michael F Holick
Journal:  Am J Med       Date:  2002-06-01       Impact factor: 4.965

2.  Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Authors:  Anna L Zisman; Marta Hristova; L Tammy Ho; Stuart M Sprague
Journal:  Am J Nephrol       Date:  2007-01-11       Impact factor: 3.754

3.  Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States.

Authors:  Robert E LaClair; Richard N Hellman; Sharon L Karp; Michael Kraus; Susan Ofner; Qian Li; Karen L Graves; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2005-06       Impact factor: 8.860

Review 4.  Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.

Authors:  Mario Cozzolino; Maurizio Gallieni; Diego Brancaccio; Teresa Arcidiacono; Giuseppe Bianchi; Giuseppe Vezzoli
Journal:  J Nephrol       Date:  2006 Sep-Oct       Impact factor: 3.902

5.  The prevalence of hypovitaminosis D among US adults: data from the NHANES III.

Authors:  Ashraf Zadshir; Naureen Tareen; Deyu Pan; Keith Norris; David Martins
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

6.  25-hydroxycholecalciferol stimulation of muscle metabolism.

Authors:  S J Birge; J G Haddad
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

7.  Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.

Authors:  Ziyad Al-Aly; Rizwan A Qazi; Esther A González; Angelique Zeringue; Kevin J Martin
Journal:  Am J Kidney Dis       Date:  2007-07       Impact factor: 8.860

8.  Prevalence of vitamin D deficiency among healthy adolescents.

Authors:  Catherine M Gordon; Kerrin C DePeter; Henry A Feldman; Estherann Grace; S Jean Emans
Journal:  Arch Pediatr Adolesc Med       Date:  2004-06

9.  Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3.

Authors:  B P Halloran; P Schaefer; M Lifschitz; M Levens; R S Goldsmith
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

Review 10.  Growth of prepubertal children on dialysis.

Authors:  Constantinos J Stefanidis; Günter Klaus
Journal:  Pediatr Nephrol       Date:  2007-03-31       Impact factor: 3.714

View more
  31 in total

1.  Vitamin D status of children receiving chronic dialysis.

Authors:  Basema I Dibas; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2012-06-03       Impact factor: 3.714

2.  Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease.

Authors:  Pankaj Hari; Nandita Gupta; Smriti Hari; Ashima Gulati; Puneet Mahajan; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2010-09-25       Impact factor: 3.714

3.  A single high dose of ergocalciferol can be used to boost 25-hydroxyvitamin D levels in children with kidney disease.

Authors:  Vladimir Belostotsky; Zulf Mughal; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2008-12-02       Impact factor: 3.714

Review 4.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

Review 5.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

Review 6.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

7.  Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease.

Authors:  Amy C Wilson; Michael F Schneider; Christopher Cox; Larry A Greenbaum; Jeffrey Saland; Colin T White; Susan Furth; Bradley A Warady; Mark M Mitsnefes
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-06       Impact factor: 8.237

8.  Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5.

Authors:  Pornpimol Rianthavorn; Pantipa Boonyapapong
Journal:  Pediatr Nephrol       Date:  2013-02-19       Impact factor: 3.714

9.  Clinical utility of vitamin d testing: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-02-01

Review 10.  Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management.

Authors:  Amy C Wilson; Mark M Mitsnefes
Journal:  Am J Kidney Dis       Date:  2009-08       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.